Auron Therapeutics is developing next-generation targeted cancer therapies by identifying and targeting the drivers of the disrupted cell states found in cancer, and reverting cancer cells from a plastic, proliferative cell state to a more mature, non-proliferative cell state. Using its AURIGIN™ platform, Auron is building a pipeline of small molecule targeted therapies, led by AUTX-703, for the treatment of both solid tumors and hematologic malignancies.

Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit
Newton, MA, October 13, 2025 – Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that members of its leadership team will participate in the 8th Annual Targeted Protein Degradation (TPD) & Induced Proximity Summit, taking place October 27-30, 2025 in Boston, MA.

